Oral Fucoidan Attenuates Lung Pathology and Clinical Signs in a Severe Influenza A Mouse Model

Fucoidans are known to be effective inhibitors of inflammation, and of virus binding and cellular entry. <i>Undaria pinnatifida</i>-derived fucoidan (UPF) was assessed in a severe influenza A (H1N1, PR8) infection model in mice. Initially, UPF was gavaged at 3.52 mg daily in a treatment...

Full description

Bibliographic Details
Main Authors: Claire Richards, Neil A. Williams, J. Helen Fitton, Damien N. Stringer, Samuel S. Karpiniec, Ah Young Park
Format: Article
Language:English
Published: MDPI AG 2020-05-01
Series:Marine Drugs
Subjects:
Online Access:https://www.mdpi.com/1660-3397/18/5/246
Description
Summary:Fucoidans are known to be effective inhibitors of inflammation, and of virus binding and cellular entry. <i>Undaria pinnatifida</i>-derived fucoidan (UPF) was assessed in a severe influenza A (H1N1, PR8) infection model in mice. Initially, UPF was gavaged at 3.52 mg daily in a treatment model. Gross lung pathology (consolidation) was significantly reduced as compared to controls. UPF was then presented as a feed supplement at a rate of either nil, 3.52 mg/day or 7.04 mg/day in a prophylactic model, dosed three days before infection. A significant improvement was observed in the clinical signs of ill-health, as well as a reduction in gross lung pathology in animals treated with the higher dose, although there was no significant reduction in lung viral titres.
ISSN:1660-3397